Targeted therapy of cancer with radiolabeled antibodies

Journal of Nuclear Medicine

Volumn 43, Issue 5, 2002, Pages 693-713

  Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibodies; Cancer; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTIBODY; ANTIBODY CONJUGATE; ASTATINE 211; AVIDIN; BIOTIN; BISMUTH; BISMUTH 212; BISMUTH 213; BISPECIFIC ANTIBODY; CD20 ANTIGEN; CHELATING AGENT; COPPER 67; EPRATUZUMAB; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IODINE 131; LUTETIUM; LUTETIUM 177; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; RADIOISOTOPE; RHENIUM 186; RHENIUM 188; RITUXIMAB; STREPTAVIDIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ALPHA RADIATION; ANAPHYLAXIS; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA RADIATION; BLADDER CARCINOMA; BONE MARROW TOXICITY; BRAIN CANCER; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; EPITHELIUM TUMOR; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HYPOTHYROIDISM; IMMUNOGENICITY; KIDNEY CARCINOMA; LINEAR ENERGY TRANSFER; MYELOID LEUKEMIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; SOLID TUMOR; T CELL LYMPHOMA; THYROID MEDULLARY CARCINOMA;

BRAIN NEOPLASMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0036255688     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (205)

1. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning
2. Radioimmuno-detection of cancer with radioactive antibodies to carcinoembryonic antigen
3. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen
4. Current status of radioimmunoglobulins in the treatment of human malignancy
5. Iodine 131-antiferritin, a new treatment modality in hepatoma: A radiation therapy oncology group study
6. Monoclonal antibodies in cancer detection and therapy
7. Radioimmunotherapy: Recent results and future directions
8. Recent progress in radioimmunotherapy for cancer
9. Advances in the use of monoclonal antibodies in cancer radiotherapy
10. Clinical radioimmunotherapy
11. Radioimmunotherapy of cancer: Using monoclonal antibodies to target radiotherapy
12. Radioimmunotherapy
13. Biological considerations for radioimmunotherapy
14. Strategies for antibody targeting
15. Experimental radioimmunotherapy. A brief overview
16. A new era for radiolabeled antibodies in cancer
17. Experimental radioimmunotherapy
18. Overview of obstacles and opportunities for radioimmunotherapy of cancer
19. 131I-antiferritin: An RTOG study
20. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease
21. Immunological considerations on the use of goat antibodies to carcinoembryonic antigen for the radioimmunodetection of cancer
22. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice
23. 2 fragments
24. Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides?
25. 2
26. 2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice
27. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments
28. Combined radioimmunotherapy and radiotherapy of liver metastases from colorectal cancer: A feasibility study
29. Radioimmunotherapy: Designer molecules to potentiate effective therapy
30. 131I-labeled p97-specific Fab fragments in human melanoma as a basis of radiotherapy
31. Use of 1-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience
32. 131I-chimeric B72.3 antibody therapy
33. Humanization of monoclonal antibodies: Molecular approaches and applications
34. Revised Nuclear Regulatory Commission's regulations for release of patients administered radioactive materials: Outpatient iodine 131 anti-B1 therapy
35. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies
36. 131I-labeled Lym-1 antibody: Comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma
37. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUCl mucin monoclonal antibody C595
38. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-I77 CC49
39. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-I77 CC49: A phase I/II study
40. A phase I trial of rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinomas: Toxicity and clinical response
41. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukemia
42. Radioimmunotherapy with alphaemitting nuclides
43. 213Bi-HuM195 (anti-CD33) in patients with leukemia
44. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy
45. 211At-rituximab against non-Hodgkin lymphoma cells
46. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
47. Development of a streptavidin anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model
48. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
49. The in vivo uses of streptavidin and biotin: A short progress report
50. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
51. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin
52. 90Y-DOTA-biotin
53. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
54. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results
55. Pretargeting of carcinomas with the avidinbiotin system
56. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin
57. Pretargeting with the affinity enhancement system for radioimmunotherapy
58. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small cell lung cancer
59. Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens. Results and clinical perspectives
60. 131I-labeled bivalent DTPA hapten in patients with CEA-expressing tumor
61. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate
62. 131I-labeled bivalent hapten
63. Radiolabeled antibody therapy of B-cell lymphomas
64. Antibody-targeted therapy for low-grade lymphoma
65. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody
66. 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL)
67. HAMA interference with murine monoclonal antibody-based immunoassays
68. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma
69. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience
70. Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL)
71. Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation
72. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
73. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
74. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: The Seattle, WA, experience
75. A phase I/II trial of iodine-131-tositumomab (anti-CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
76. 90Y-Zevalin (yttriumibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
77. Final results of a randomized controlled study of the Zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
78. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
79. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma
80. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL)
81. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
82. Immunotherapy of NHL with Epratuzumab (anti-CD22 monoclonal antibody): Excellent tolerability with objective responses
83. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma
84. Lymphoma imaging with a new technetium-99m labeled antibody, LL2
85. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas
86. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2
87. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
88. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
89. 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
90. 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas
91. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody
92. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
93. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing
94. A phase I/II trial with Y-90 hLL2 in recurrent B-cell lymphomas, preliminary results [abstract]
95. 186Re-hLL2 [abstract]
96. Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
97. Yttrium-90 anti-CD19 radioimmunotherapy for lymphoma
98. Radioimmunotherapy of lymphoma: A UC Davis experience
99. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
100. 1311-Lym-1 antibody
101. 67Copper-2-iminothiolane-6-[p-(bromocetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma
102. 131I-Lym-1
103. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: The coming of age of radioimmunotherapy
104. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease
105. 131I-labeled monoclonal antibody: An Illinois Cancer Council study
106. 90Y-T101, in patients with CD5-expressing leukemia and lymphoma
107. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias
108. A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity
109. Molecular remission induction with retinoic acid and anti-CD3 monoclonal antibody HuM195 in acute promyelocytic leukemia
110. 131I anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
111. 131I anti-CD45 antibody plus busulfan/cyclophosphamide in matched transplants for AML in first remission
112. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma
113. 213Bi-α radioimmunotherapy for multiple myeloma
114. Advantage of dose fractionation in monoclonal-antibody-targeted radioimmunotherapy
115. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer
116. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach
117. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
118. 125I-monoclonal antibody in the management of primary glioblastoma multiforme
119. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase
120. Iodine 125-labeled anti-epidermal growth factor receptor 425 in the treatment of malignant astrocytomas: A pilot study
121. 125I-labeled monoclonal antibody against epidermal growth factor receptor
122. Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration
123. 131I-3F8
124. Meningeal leukemia and medulloblastoma: Preliminary experience with intrathecal radioimmunotherapy
125. Monoclonal antibodies in the treatment of central nervous system malignancies
126. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis
127. The long term survival of patients with ovarian cancer treated with radioimmunotherapy
128. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies
129. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma
130. 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer
131. 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity
132. Prospects of radioimmunotherapy in pithelial ovarian cancer: Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies
133. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody
134. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma
135. Targeted therapy of athymic mice bearing GW-39 human-colonic-cancer micrometastases with 1-131 labeled monoclonal antibodies
136. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy
137. 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model
138. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors
139. Radioimmunotherapy of micrometastases: Sidestepping the solid tumor hurdle
140. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: Preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study
141. 131I-labeled humanized anti-CEA antibody, hMN-14
142. Treatment of metastatic colorectal cancer by means of specific monoclonal antibodies conjugated with iodine 131: A phase II study
143. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
144. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin antibodies
145. Radioimmunotherapy of colorectal cancer liver metastases: Combination with radiotherapy
146. Radioimmunotherapy of colorectal cancer
147. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial
148. 90yttrium-labeled monoclonal antibody CC49: A phase I trial
149. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily
150. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer
151. Breast cancer imaging with radiolabeled antibodies
152. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma
153. Initial clinical experience evaluating yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer
154. A novel anti-breast epithelial mucin MoAb (BrE-3)
155. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: A comparative study
156. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous hematopoietic stem cell support (AHSCS) in patients with refractory metastatic breast cancer
157. The biologic window for chimeric L6 radioimmunotherapy
158. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions
159. Radioimmunotherapy for advanced breast cancer using 1-131-ChL6 antibody
160. 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A
161. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma
162. 131I-labeled monoclonal antibody CC49 in breast cancer: A phase II trial
163. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment
164. Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging
165. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
166. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer
167. 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer
168. 90Y-CYT-356 monoclonal antibody
169. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy
170. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
171. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy
172. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
173. 213Bi]J591) for radioimmunotherapy of prostate cancer
174. 90Y-DOTA-peptide-ChL6 for PC3-tumored mice
175. Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer
176. Intravesical administration of radiolabeled tumour-associated monoclonal antibody in bladder cancer
177. Targeted diagnosis and treatment of superficial bladder cancer with monoclonal antibody BDI-1
178. 131I-labeled chimeric monoclonal antibody G250
179. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
180. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated does radioimmunotherapy
181. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial
182. 2 anti-carcinoembryonic antigen Mab and AHSCR
183. 90Y labeled Mabs
184. 90Y-labeled anti-Lewis Y monoclonal antibody B3
185. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors
186. Radioimmunologic targeting and therapy with antihuman primary hepatic cancer monoclonal antibodies (Hepama I) in patients
187. Immunoradiotherapy for primary nonresectable hepatocellular carcinoma
188. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit
189. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: Results of a phase I/II trial
190. Radioimmunotherapy dose estimation in patients with B-cell lymphoma
191. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy
192. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma
193. Phase I trial of targeted alpha-particle therapy for myeloid leukemias with bismuth-213-Hum195 (anti-CD33)
194. 131Lym-1 in patients with non-Hodgkin's lymphoma
195. Imaging and treatment of B-cell lymphoma
196. 131I-CC49 in colorectal cancer
197. Radionuclide dosimetry and radioimmunotherapy of cancer
198. 90yttrium radioimmunotherapy trial in non-Hodgkin's lymphoma (NHL)
199. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma
200. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
201. Dose-rate effects between 0.3 and 30 Gy/h in a normal and a malignant human cell line
202. Dose-rate effect between 1 and 10 Gy/min in a mammalian cell culture
203. 131I-labeled anti-carcinoembryonic antigen antibodies
204. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy